Join to View Full Profile
no officeKnoxville, TN 37919
Phone+1 704-517-0220
Dr. Kaufman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Michael Kaufman lives in Knoxville, TN, He received his medical degree from Duke University School of Medicine in 1971, completed his residency in Neurology at Case Western Reserve University/Clevland General Hospital, and a fellowship Mayo Clinic College of Medicine and Science. Dr. Kaufman has served as am Assistant Professor at Duke University Hospital, , Professor of Neurology at Atrium Health in Charlotte, NC, and a Staff Physician at University of Tennessee Medical Center in Knoxville. He has been recognized as a Most Compassionate Physician, Best Doctors of American, and National MS Society Volunteer Hall of Fame. He has participated in committees for the National MS Society, the Consortium of MS Centers, and the Department of Defense MS Research Program. Dr. Kaufman has participated in many clinical trials, and authored multiple publications. He retired from clinical practice in 2015.
Education & Training
- Mayo Clinic College of Medicine and Science (Rochester)Residency, Neurology, 1975 - 1976
- Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Neurology, 1972 - 1975
- New York Presbyterian Hospital (Cornell Campus)Internship, Internal Medicine, 1971 - 1972
- Duke University School of MedicineClass of 1971
- Union CollegeBachelors, 1963 - 1967
Certifications & Licensure
- NC State Medical License 1977 - 2015
- TN State Medical License 2014 - 2015
- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Clinical Care Committee National MS Society, 2006-2013
- President Consortium of MS Centers, 2010-2012
- Heatlth Care Delivery and Policy Research Committee National MS Society, 2005-2011
- Join now to see all
Publications & Presentations
PubMed
- 20 citationsRadiologic MS disease activity during natalizumab treatment interruption: findings from RESTOREMichael Kaufman, Bruce A.C. Cree, Jérôme De Seze, Robert J. Fox, Ralf Gold
Journal of Neurology. 2015-02-01 - 60 citationsNatalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis.Michael Kaufman, Gabriel Pardo, Howard Rossman, Marianne T. Sweetser, Fiona Forrestal
Journal of the Neurological Sciences. 2014-06-15 - 17 citationsHLA DR and DQ alleles and haplotypes associated with clinical response to glatiramer acetate in multiple sclerosis.Suhayl Dhib-Jalbut, Reuben M. Valenzuela, Kouichi Ito, Michael Kaufman, Mary Ann Picone
Multiple Sclerosis and Related Disorders. 2013-10-01
Journal Articles
- MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption studyFox RJ, Cree BA, De Seze J, Gold R, Hartung HP, Jeffery D, Kappos L, Kaufman M, Montalbán X, Weinstock-Guttman B, Anderson B, Natarajan A, Ticho B, Duda P, Neurology, 1/1/2014
- HLA DR and DQ predict response to glatiramer acetate in multiple sclerosisDhib-Jalbut S, Valenzuela RM, Ito K, Kaufman M, Picone M, Buyske S, Mult Scler Rel Dis, 1/1/2013
- Course of relapsing-remitting MS before, during, and after natalizumabKaufman MD, Lee R, Norton HJ, Multiple Sclerosis J, 1/1/2011
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Brain MRI results of DECIDE: a randomized, double-blind trial of DAC HYP vs. IFNbeta-1a in RRMS patients. PosterDouglas L Arnold, Ludwig Kappos, Eva Havrdova, Krzysztof Selmaj, Alexey Boyko, Michael Kaufman, Heinz Wiendl, John Rose, Steven Greenberg, Eren Demirhan, Katherine Rie..., Joint ACTRIM-ECTRIMS meeting, Boston, MA, 1/10/2014
- Safety and tolerability of daclizumab HYP treatment in relapsing-remitting multiple sclerosis.Krzysztof Selmaj, Ludwig Kappos, Douglas L. Arnold, Eva Havrdova, Alexey Boyko, Michael Kaufman, Heinz Wiendl, John Rose, Steven Greenberg, Eren Demirhan, Katherine Ri..., Joint ACTRIM-ECTRIMS meeting, Boston, MA, 1/10/2014
- Primary results of DECIDE: a randomized, double-blind, double-dummy, active-controlled trial of Daclizumab HYP vs. Interferon beta-1a in RRMS patients.Ludwig Kappos, Krzysztof Selmaj, Douglas Arnold, Eva Havrdova, Alexey Boyko, Michael Kaufman, Heinz Wiendl, John Rose, Steven Greenberg, Eren Demirhan, Marianne Sweets..., Joint ACTRIM-ECTRIMS meeting, Boston, MA, 1/10/2014
- Join now to see all
Other
- CME article: How to Choose an Immunomodulator in 2010 and Beyond.Kaufman MD
http://cme.medscape.com/viewprogram/31525
1/25/2010
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: